Analysis of cancer genomes reveals basic features of human aging and its role in cancer development

Nature Communications

Volumn 7, Issue , 2016, Pages

  Podolskiy, Dmitriy I ^a   Lobanov, Alexei V ^a   Kryukov, Gregory V ^b   Gladyshev, Vadim N ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; CANCER; GENOME; MORTALITY; MUTATION; PHYSIOLOGY; RISK FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; AGING; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER INCIDENCE; CARCINOGENESIS; COLON ADENOCARCINOMA; FEMALE; GENITAL SYSTEM; HUMAN; HUMAN GENOME; LIVER CELL CARCINOMA; MALE; MELANOMA; MUTATION ACCUMULATION; MUTATIONAL LOAD; OVARY CYSTADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROSTATE ADENOCARCINOMA; RECTUM CARCINOMA; RISK FACTOR; SEX DIFFERENCE; SILENT MUTATION; SOMATIC MUTATION; STOMACH ADENOCARCINOMA; UTERINE CERVIX CARCINOMA; ADOLESCENT; ADULT; AGE; AGED; DNA MUTATIONAL ANALYSIS; GENETICS; INCIDENCE; MIDDLE AGED; MUTATION; NEOPLASM; PROCEDURES; SEX FACTOR; WHOLE EXOME SEQUENCING; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGING; CARCINOGENESIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENOME, HUMAN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; RISK FACTORS; SEX FACTORS; WHOLE EXOME SEQUENCING; YOUNG ADULT;

EID: 84982306582     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12157     Document Type: Article

References (55)

1. Sanders, S. J. et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485, 237-241 (2012).
2. Neale, B. M. et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485, 242-245 (2012).
3. O'Roak, B. J. et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485, 246-250 (2012).
4. Kong, A. et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature 488, 471-475 (2012).
5. Bender, A. et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515-517 (2006).
6. Coskun, P. E., Beal, M. F. & Wallace, D. C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl Acad. Sci. USA 101, 10726-10731 (2004).
7. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
8. Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 75, 685-705 (2013).
9. de Magalhães, J. P. How ageing processes influence cancer. Nat. Rev. Cancer 13, 357-365 (2013).
10. Lynch, M. Rate, molecular spectrum, and consequences of human mutation. Proc. Natl Acad. Sci. USA 107, 961-968 (2010).
11. Vijg, J. & Suh, Y. Genome instability and aging. Annu. Rev. Physiol. 75, 645-668 (2013).
12. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
13. Tomasetti, C., Vogelstein, B. & Parmigiani, G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumour initiation. Proc. Natl Acad. Sci. USA 110, 1999-2004 (2013).
14. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
15. Weinstein, J. N. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113-1120 (2013).
16. Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. New Engl. J. Med. 371, 2477-2487 (2014).
17. Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. New Engl. J. Med. 371, 2488-2498 (2014).
18. Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 47, 1402-1407 (2015).
19. Milholland, B., Auton, A., Suh, Y. & Vijg, J. Age-related somatic mutations in the cancer genome. Oncotarget 6, 24627-24635 (2015).
20. Harding, C., Pompei, F., Lee, E. E. & Wilson, R. Cancer suppression at old age. Cancer Res. 68, 4465-4478 (2008).
21. Harding, C., Pompei, F. & Wilson, R. Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer 118, 1371-1386 (2012).
22. CDC WONDER online database. United States Cancer Mortality Statistics: 1998-2011. Department of Health and Human Services, Centers for Disease Control and Prevention (2014) (accessed on 25 January 2016).
23. Cancer Research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type (accessed 28 January 2016).
24. Australian Government, Cancer Australia. https://canceraustralia.gov.au/affected-cancer/cancer-statistics (accessed 27 January 2016).
25. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013).
26. Alexandrov, L. B. & Stratton, M. R. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr. Opin. Genet. Dev. 24, 52-60 (2014).
27. Francioli, L. C. et al. Genome-wide patterns and properties of de novo mutations in humans. Nat. Genet. 47, 822-826 (2015).
28. Brown, P. O. & Palmer, C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 6, e1000114 (2009).
29. Jones, S. et al. Comparative lesion sequencing provides insights into tumour evolution. Proc. Natl Acad. Sci. USA 105, 4283-4288 (2008).
30. Klein, C. A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9, 302-312 (2009).
31. van Oortmarssen, G. J. & Habbema, J. D. Epidemiological evidence for agedependent regression of pre-invasive cervical cancer. Br. J. Cancer 64, 559-565 (1991).
32. Peer, P. G. M., Van Dijck, J. A. A. M., Verbeek, A. L. M., Hendriks, J. H. C. L. & Holland, R. Age-dependent growth rate of primary breast cancer. Cancer 71, 3547-3551 (1993).
33. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
34. Bialecki, E. S. & Di Bisceglie, A. M. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 7, 26-34 (2005).
35. Friberg, S. & Mattson, S. On the growth rates of human malignant tumours: implications for medical decision making. J. Surg. Oncol. 65, 284-297 (1997).
36. Furukawa, H., Iwata, R. & Moriyama, N. Growth rate of pancreatic adenocarcinoma: initial clinical experience. Pancreas 22, 366-369 (2001).
37. Haruma, K. et al. Evaluation of tumour growth rate in patients with early gastric carcinoma of the elevated type. Gastrointest. Radiol. 16, 289-292 (1991).
38. Ozono, S. Tumour doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn. J. Clin. Oncol. 34, 82-85 (2004).
39. Schmid, H.-P., McNeal, J. E. & Stamey, T. A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71, 2031-2040 (1993).
40. Wang, J. C. et al. Rapidly growing small peripheral lung cancers detected by screening CT: correlation between radiological appearance and pathological features. Br. J. Radiol. 73, 930-937 (2000).
41. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
42. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014).
43. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
44. Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015).
45. Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015).
46. Roberts, S. A. & Gordenin, D. A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786-800 (2014).
47. Hoeijmakers, J. H. J. DNA damage, aging, and cancer. New Engl. J. Med. 361, 1475-1485 (2009).
48. Schelter, B., Winterhalder, M. & Timmer, J. Handbook of Time Series Analysis: Recent Therorectical Developments and Applications (eds John Wiley & Sons, 2006).
49. Armitage, P. & Doll, R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 8, 1-12 (1954).
50. Gladyshev, V. N. Aging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environmental, and stochastic processes. Aging Cell. doi:10.1111/acel.12480 (2016).
51. Cook, M. B. et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol. Biomarkers Prev. 18, 1174-1182 (2009).
52. Cook, M. B., McGlynn, K. A., Devesa, S. S., Freedman, N. D. & Anderson, W. F. Sex disparities in cancer mortality and survival. Cancer Epidemiol. Biomarkers Prev 20, 1629-1637 (2011).
53. Gladyshev, V. N. The origin of aging: imperfectness-driven non-random damage defines the aging process and control of lifespan. Trends Genet. 29, 506-512 (2013).
54. Vaupel, J. W. Biodemography of human ageing. Nature 464, 536-542 (2010).
55. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).